A2 Biotherapeutics Inc.

Privately held: no public share price · United States

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
3Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 1/2
EGFR (activator) / HLA-A*02 (blocker)Cell therapy
Non-Small Cell Lung Cancer
Phase 1/2
CEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)Cell therapy
Non-Small Cell Lung CancerColorectal CancerPancreatic Cancer
Phase 1/2
Mesothelin/MSLN (activator) / HLA-A*02 (blocker)Cell therapy
Non-Small Cell Lung Cancer
Phase 1/2
Mesothelin/MSLN (activator) / HLA-A*02 (blocker)Cell therapy
Non-Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
A2B530Phase 1/2Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer …
Est. primary completion 2026-12 · NCT05736731 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
A2B543 + A2B694Phase 1/2Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer …
Est. primary completion 2028-06 · NCT06051695 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
A2B395Phase 1/2Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer …
Est. primary completion 2029-03-31 · NCT06682793 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.